Section Arrow
GOVX.NASDAQ
- GeoVax Labs Inc.
Quotes are at least 15-min delayed:2026/07/15 17:23 EDT
After Hours
Last
 1
-0.01 (-0.99%)
Bid
1.01
Ask
1.02
High 1.01 
Low
Volume 28 
Regular Hours (Closed)
Last
 1.01
-0.04 (-3.81%)
Day High 
1.045 
Prev. Close
1.05 
1-M High
1.43 
Volume 
335.86K 
Bid
1.01
Ask
1.02
Day Low
0.9899 
Open
1.04 
1-M Low
1.05 
Market Cap 
5.47M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.18 
20-SMA 1.23 
50-SMA 1.59 
52-W High 23.1 
52-W Low 0.9631 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.82/-1.79
Enterprise Value
6.05M
Balance Sheet
Book Value Per Share
0.09
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.49M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VIVSVivoSim Lab Inc0.8529+0.0181+2.17%0.47PE
After Hours 0.835 -0.0179 -2.10%
LIMNLiminatus Pharma Inc0.1145+0.011+10.63%-- 
After Hours 0.12 +0.0055 +4.80%
IOVAIovance Biotherapeutics4.74+0.81+20.61%-- 
After Hours 4.7001 -0.0399 -0.84%
ERNAErnexa Therapeutics Inc.6.73+0.67+11.06%0.01PE
After Hours 7.2 +0.47 +6.98%
PHIOPhio Pharmaceuticals Corp0.8901-0.1399-13.58%-- 
After Hours 0.9473 +0.0572 +6.43%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.